Breaking News, Collaborations & Alliances

Almac, Pfizer, PETACC3 Enter Research Pact

Almac, Pfizer and the PETACC3 Translational Research Working Party (PTRW) will conduct a collaborative study involving gene expression profiling of formalin-fixed paraffin-embedded (FFPE) samples from the Pan-European Trials in Adjuvant Colon Cancer (PETA

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Almac, Pfizer and the PETACC3 Translational Research Working Party (PTRW) will conduct a collaborative study involving gene expression profiling of formalin-fixed paraffin-embedded (FFPE) samples from the Pan-European Trials in Adjuvant Colon Cancer (PETACC 3) trial. The study will use Almac Diagnostic’s Colorectal Cancer DSA research tool to identify molecular subtypes, biomarkers and drug targets. The samples to be used in the study are taken from the PETACC 3 study, an international...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters